Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Cancer Lett. 2020 Dec 21;500:220–227. doi: 10.1016/j.canlet.2020.12.023

Fig. 5.

Fig. 5.

NSCLC xenograft growth delay is enhanced by YTR107. A549 xenograft-bearing mice were subjected to a 7-day regimen consisting of YTR107 (20 mg/kg) or solvent control (DMSO) administered IP 1 h before tumors received 0 or 2.2-Gy. Tumor growth curves are shown in panel (A). Days (±SD) required to achieve a 5-fold increase tumor volume are plotted in (B). (C) Kaplan Meier survival analysis. A549 xenograft-bearing mice were subjected to a 7-day regimen consisting of YTR107 (20 mg/kg) or solvent control (DMSO) administered IP 1 h before tumors received 0 or 2.2-Gy.